The mysteries of the cosmos revealed at Idyllwild speaker series

Larry Kawano Photo courtesy of Larry Kawano

Many know Larry, or more properly, Dr. Kawano doctorate in cosmology from the University of Chicago, bachelor of science in physics from Cornell University and postgraduate study at CalTech as a member of the Idyllwild Master Chorale and as a gifted and extraordinarily funny actor in IMCs summer theater offerings. Larry may seem unassuming but his academic pedigree and wealth of knowledge about all things astronomical and cosmological is very impressive indeed.

Ask him a simple question such as What was there before the Big Bang? and he will give you nuanced answers, analogies and explanations that even the most unschooled layperson can grasp. And hell do it in a way that leaves you thinking and smiling, informed, intrigued and wanting to know more. We at Astrocamp are all about fun, said Kawano, who is curriculum director and science interpretives creator at Idyllwilds Astrocamp, explaining why he mixes smiles with substance and comedy with cosmology.

Ill be discussing six topics covering the span of the universe about which people might have misconceptions: planets, our sun (Sol), black holes, the Milky Way, the Big Bang, and [our] universe. Ill ask a question of the audience to see what their current perceptions are about that subject and then discuss how, in science, things and concepts are always changing. Thats the nature of things. In science, things are always changing.

When prodded for an example, using the Big Bang, Kawano answered, Many think about the Big Bang as an explosion, hence the outward expansion of the universe. But thats not so. Come to the presentation to hear his metaphoric explanation comparing the universe to a gigantic dance floor with tiles on the dance floor, too close together with dancers standing on the tiles, and then, over time, the tiles with the dancers begin slowly and inexorably moving farther and farther away from each other. The question is why, what started it, and what preceded it.

Kawano compares the most efficient way to explore space and other star systems and galaxies (using self replicating machines) with the challenge of visiting the unexplored depths of our own planets seas (James Camerons recent dive makes him the third person to have dived that deep and seen the landscape Cameron described as very lunar, very desolate.) Both space and deep sea exploration are better ways to understand what our home [the Earth] is like, said Kawano.

Kawanos presentation, Astro Mythbusters will be 6 p.m., Wednesday, May 16, at Silver Pines Lodge. There will be a wine and cheese reception before his talk. Both are free to the public.

Category: On The Town

Read the original post:

The mysteries of the cosmos revealed at Idyllwild speaker series

Moving Beyond the Marketing Funnel: Rocket Fuel and Forrester Research Announce Free Webinar

REDWOOD SHORES, CA--(Marketwire -05/09/12)- Rocket Fuel, the leading provider of artificial-intelligence advertising solutions for digital marketers, today announced a free webinar to be held on Wednesday, May 30th at 11 am PT. Marketers can sign up for the webinar at http://rocketfuel.com/newsroom/event/webinar-cpg-in-the-digital-age-ditch-the-funnel-embrace-the-lifecycle.

Key Facts:

Resources:

About Rocket Fuel:Rocket Fuel is the leading provider of artificial-intelligence advertising solutions that transform digital media campaigns into self-optimizing engines that learn and adapt in real-time, and deliver outstanding results from awareness to sales. Recently awarded #22 in Forbes Most Promising Companies in America list, over 400 of the world's most successful marketers trust Rocket Fuel to power their advertising across display, video, mobile, and social media. Founded by online advertising veterans and rocket scientists from NASA, DoubleClick, IBM, and Salesforce.com, Rocket Fuel is based in Redwood Shores, California, and has offices in eleven cities worldwide including New York, London, and Toronto.

About Forrester Research:Forrester Research, Inc. is an independent research company that provides pragmatic and forward-thinking advice to global leaders in business and technology. Forrester works with professionals in 19 roles at major companies providing proprietary research, customer insight, consulting, events, and peer-to-peer executive programs. For more than 28 years, Forrester has been making IT, marketing, and technology industry leaders successful every day. For more information, visit http://www.forrester.com.

2012 Rocket Fuel Inc. All rights reserved. Rocket Fuel Inc. is a registered trademark of Rocket Fuel Inc. in the U.S. and/or other countries. All other trademarks are the property of their respective owners.

See the original post:

Moving Beyond the Marketing Funnel: Rocket Fuel and Forrester Research Announce Free Webinar

Google Driverless Car Ok'd by Nevada

Home > Video > Money > Business News

Housing Ideas to Help Create Jobs

Woman Says Cancer Diagnosis Got Her Fired

Google Driverless Car Ok'd by Nevada

'Avengers' Dominates Box Office

'Austerity' Revolt in Europe: Effect in U.S.?

Associated Press Apologizes to WWII Reporter

Search Intensifies for Missing Tennessee Mother

Bringing America Back: Working on the Railroad

Jobs Report: Numbers Weaker Than Hoped

Go here to see the original:

Google Driverless Car Ok'd by Nevada

Percipio Media, LLC Proudly Accepts Partnership With MIT's Prestigious Computer Science And Artificial Intelligence …

CAMBRIDGE, Mass., May 9, 2012 /PRNewswire/ -- Percipio Media is honored to accept an invitation to the MIT Computer Science and Artificial Intelligence Laboratory's (CSAIL) coveted Industry Affiliates Program (IAP).

CSAIL is the largest independent laboratory at MIT and one of the world's most important centers of information technology research. The lab and its members have played a huge role in the technology revolution of the past 50 years. Elizabeth Bruce, Director Industry Partnerships MIT CSAIL, stated, "Percipio Media is an ideal candidate for our Industry Affiliates Program. We highly respect Fred Goff and the Percipio team and we very much look forward to successful research collaborations and partnerships with them."

Percipio leverages machine-learning techniques in fields of asset management and Internet commerce. Percipio Media is emerging as one of the fastest growing companies in Boston and has single handedly grown a community in the career and education space of over 15 million members in the last 2 years. "We are thrilled and honored to become a partner of CSAIL and look forward to actively supporting what is clearly one of the greatest institutions of higher learning in the world," said Frederick Goff, CEO of Percipio Media, LLC. "Our data science team has for years been developing proprietary machine learning techniques to distill value in what is now termed 'big data' space; as such, collaborations with MIT faculty, students and researchers in cutting edge computer science techniques is a natural and exciting fit."

CSAIL IAP extends its company members access to work in partnership with MIT's vast resources. Faculty, current research and most importantly, its students and their ideas are accessible through IAP membership. All members of CSAIL and IAP are working in unison to shape the future of information technology.

To learn more about Percipio Media LLC log on to: http://www.percipiomedia.com/, fill out the contact form and find out how their data-driven approach to online media can help grow your business. For more information about the CSAIL and its Industry Affiliates Program go to: http://www.csail.mit.edu/.

Contact: Chassie Guinn, 617-758-2001, chassie@percipiomedia.com

See the original post:

Percipio Media, LLC Proudly Accepts Partnership With MIT's Prestigious Computer Science And Artificial Intelligence ...

LMI Aerospace Beats Analyst Estimates on EPS

LMI Aerospace (Nasdaq: LMIA) reported earnings on May 7. Here are the numbers you need to know.

The 10-second takeawayFor the quarter ended March 31 (Q1), LMI Aerospace met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded and GAAP earnings per share increased.

Gross margins improved, operating margins dropped, net margins increased.

Revenue detailsLMI Aerospace booked revenue of $66.7 million. The three analysts polled by S&P Capital IQ wanted to see a top line of $67.4 million on the same basis. GAAP reported sales were 9.6% higher than the prior-year quarter's $60.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS detailsEPS came in at $0.41. The three earnings estimates compiled by S&P Capital IQ averaged $0.39 per share. GAAP EPS of $0.41 for Q1 were 11% higher than the prior-year quarter's $0.37 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin detailsFor the quarter, gross margin was 24.7%, 80 basis points better than the prior-year quarter. Operating margin was 11.1%, 50 basis points worse than the prior-year quarter. Net margin was 7.2%, 20 basis points better than the prior-year quarter.

Looking aheadNext quarter's average estimate for revenue is $70.2 million. On the bottom line, the average EPS estimate is $0.44.

Read more from the original source:

LMI Aerospace Beats Analyst Estimates on EPS

AeroMechanical Services (TSX VENTURE:AMA) Name Change to FLYHT Aerospace Solutions Ltd. (TSX VENTURE:FLY)

CALGARY, ALBERTA--(Marketwire - May 10, 2012) - AeroMechanical Services Ltd. (AMA.V - News) shareholders approved a Company name change to FLYHT Aerospace Solutions Ltd. (the "Company" or "FLYHT") at the Annual General Meeting held yesterday afternoon in Calgary, AB. Subject to the approval of the TSX Venture Exchange, the new ticker symbol on the TSX-V will be "FLY". It is anticipated that FLYHT will commence trading under its new symbol in the next couple days.

"The Company has been operating under the FLYHT brand name for the past five years, so the name is already established in the industry," remarked President and CEO Bill Tempany. "We believe that the name change throughout the whole Company will have a positive outcome on our business because there will be consistency among all stakeholder groups in operations, marketing and investor relations."

AeroMechanical Services Ltd. was formed in 1998 and began trading as "AMA" on the TSX Venture Exchange in 2003. Since that time, the Company's business has grown and evolved. Originally, the Company sold parts, maintenance and certification services for aircraft. When the Company recognized aircraft operators needed to be better connected with their aircraft, it shifted its focus to providing real-time data and satellite communications.

In 2007, the FLYHT brand name was introduced to as a way to differentiate products and services in the marketplace and create a new image for the Company. The Company has undergone efforts to increase marketing under the name with a launch of a new website in the first quarter of 2011 and a new logo in the third quarter of 2011.

"The origin of the FLYHT name comes from the old English spelling of the word flight and was chosen as a fitting and unique title for a company in the aerospace industry," added Mr. Tempany.

After the name change, the Company's organizational structure and operating standards will remain the same. Over the next couple days, the updated name will appear on the TSX Venture Exchange and other trading websites. All efforts have been made to ensure a smooth transition through the change for people searching both the old and new Company name.

About FLYHT Aerospace Solutions Ltd.

FLYHT provides proprietary technological products and services designed to reduce costs and improve efficiencies in the airline industry. The Company has patented and commercialized three products and associated services currently marketed to airlines, manufacturers and maintenance organizations around the world. Its premier technology, AFIRS(TM) UpTime(TM), allows airlines to monitor and manage aircraft operations anywhere, anytime, in real-time. If an aircraft encounters an emergency, FLYHT's triggered data streaming mode, FLYHTStream(TM), automatically streams vital data, normally secured in the black box, to designated sites on the ground in real-time. The Company has been publicly traded on the TSX Venture Exchange since 2003 and recently changed its trading symbol from AMA to FLY. Shareholders approved a Company name change from AeroMechanical Services Ltd. to FLYHT Aerospace Solutions Ltd. in May 2012.

AFIRS, UpTime, FLYHT, FLYHTStream and aeroQ are trademarks of FLYHT Aerospace Solutions Ltd.

Join us on social media!

More here:

AeroMechanical Services (TSX VENTURE:AMA) Name Change to FLYHT Aerospace Solutions Ltd. (TSX VENTURE:FLY)

Strategic Aerospace Sourcing in Mexico Topic of Offshore Group Podcast

TUCSON, Ariz., May 9, 2012 /PRNewswire/ -- Sourcing professional, Mike Smith, recently spoke with The Offshore Group concerning his four and one half year experience developing a Mexico supply chain for a major aerospace OEM.

Over the course of the approximately thirty minute session, Smith provides a West to East, North to South geographic overview of the composition of Mexico's rapidly developing aerospace industry that examines electronics and non-complex subassemblies in Mexicali and Baja California; aero engine parts in Guaymas, Sonora; aero structures in Chihuahua; a diversity of aerospace related activities in Monterrey; repair, maintenance and overhaul activities in Queretaro; and the emergence of Guadalajara as an area of high-tech specialization.

When visiting the site of each of Mexico's principle aerospace manufacturing clusters, Smith took note of a young, Mexican workforce eager to acquire the skills necessary to work for companies that are taking their places in Mexico's aerospace supply chain.

He noted that, "Mexico graduates several thousand engineers a year. They are enthusiastic young people, and are looking for the opportunity to qualify for jobs in the Mexican aerospace industry. They are signing up for industry training activities, and are continuing their studies with regard to operating machinery, assuring part quality, as well as in other areas necessary to perform in a modern manufacturing environment."

Smith is a member of a group called IMAC (the Independent Mexico Advisory Council). Its members help small and mid-sized aerospace companies seeking to establish facilities in Mexico to support OEM activities as part of their growing supply chain efforts. IMAC assists manufacturers in finding synergies, and also provides guidance with federal, state and local government issues related to Mexico's growing aerospace industry.

The Offshore Group is the largest provider of outsourced business support, "shelter" services in Mexico. Currently 61 businesses operate at The Offshore Group's three Mexico manufacturing industrial parks in the State of Sonora, the city of Saltillo, Coahuila, and at the Group's Vangtel subsidiary in Hermosillo. Vangtel offers Mexico shelter services to companies that occupy the call center, IT development and BPO markets, while the International Logistic Solutions Company (ILS) is a leading provider of supply chain services. The Offshore Group has recently initiated operations in Mexico's second largest city, Guadalajara. Sign up to receive information via Offshore Group RSS Feeds.

Website: http://www.offshoregroup.com

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

Visit link:

Strategic Aerospace Sourcing in Mexico Topic of Offshore Group Podcast

PASSUR Aerospace Promotes Tom White and Renee Alter and Hires Bill Leber

STAMFORD, Conn., May 9, 2012 /PRNewswire/ -- PASSUR Aerospace, Inc. (PSSR.PK), a business intelligence software and solutions company, announced the promotions of Tom White to Executive Vice President, Operations, and Renee Alter to Vice President, Airports, and the hiring of Bill Leber as Vice President, Air Traffic Innovations.

Mr. White joined the company in 2007 as a consultant and in 2008 became an employee and the Director of Air Traffic Management. He was promoted to Vice President of Air Traffic Management in 2010, and Senior Vice President of Technology and Air Traffic Management in 2011. Prior to joining the company, Mr. White spent 32 years in government service with the FAA and the U.S. Military. Between 2002 and 2007 he was a Senior Manager for the FAA in New York. Before joining the FAA, he was a U.S. Army Special Ops helicopter pilot serving with TF 160th.

Ms. Alter has over 20 years of aviation experience. She joined the company in May 2005 as Regional Sales Director. Prior to joining the company, Ms. Alter served as the Environmental Manager at the Westchester County Airport from 1999 to 2005. During that time, she successfully led the airport through the development and implementation of an Environmental Management System certified to the ISO 14001 Standard. She also holds a commercial pilot license.

Mr. Leber brings a rich aviation background to PASSUR. An airline operations expert, he has been a participant and leader in Collaborative Decision Making (CDM) development since the early 1990s. Most recently he was Research Analyst, Principal, and Senior Manager for Lockheed Martin in business development for their Collaborative ATM Practice. He has a combined 26 years of air traffic management experience at Northwest Airlines and Delta Air Lines, including work as Chief Flight Dispatcher. Mr. Leber is a leader and active member of a number of industry groups, including the FAA's REDAC - NAS Operations Subcommittee where he was Co-Chair of the Weather - ATM Integration Work Group. He is a former Chair of the CDM Future Concepts WG and was Co-Chair of ATA's overall CDM effort from 2001 to 2004. Mr. Leber is also former President and Co-Founder of the Airline Dispatchers Federation, a non-union professional association.

"PASSUR's team is its most valuable asset and I am always pleased when we can recognize talent from both within the company and from the broader industry," said Jim Barry, PASSUR Aerospace's President & CEO. "Tom has been instrumental in the growth and sophistication of PASSUR's capabilities in air traffic management, and more broadly in technology design for all markets. Renee has been the leader in PASSUR's airport market, most recently spearheading the launch of the innovative Airport Information Network. Bill is one of the most highly respected and accomplished air traffic management leaders in the industry, and will add an important new dimension to PASSUR's long-range product planning."

About PASSUR Aerospace

PASSUR Aerospace, Inc. is a business intelligence company that provides predictive analytics built on proprietary algorithms and the concurrent integration and simultaneous mining of multiple databases. We believe PASSUR is the industry standard in business intelligence dashboards and predictive analytics for aviation organizations. PASSUR serves dozens of airlines (including six of the top eight North American airlines, and all five of the top hub carriers), approximately 60 airport customers (including 23 of the top 30 North American airports), and approximately 200 corporate aviation customers, as well as the U.S. government, including the Federal Aviation Administration (FAA) and the Transportation Security Administration (TSA). PASSUR's system provides coast-to-coast coverage and is driven by proprietary, patented, business intelligence software, which is powered by a unique North American network of 155 passive radars, company owned. Supplementary, detailed coverage is also provided at 98 of the top 100 North American airports. Other PASSURs are located in Europe and Asia. Flight tracks are updated between 1 and 4.6 seconds, thereby making available a system which is user-friendly and useful for decision-making. Visit PASSUR Aerospace's website at http://www.passur.com for updated news, products, and solutions.

The forward-looking statements in this press release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those related to customer needs, budgetary constraints, competitive pressures, the success of airline trials, the profitable use of the Company's owned PASSURs located at major airports, the Company's maintenance of above average quality of its product and services, as well as potential regulatory changes. Further information regarding factors that could affect the Company's results is contained in the Company's SEC filings, including the October 31, 2011 Form 10-K and January 31, 2012 Form 10-Q.

Contact: Ron Dunsky (203) 622-4086 rondunsky@passur.com

See original here:

PASSUR Aerospace Promotes Tom White and Renee Alter and Hires Bill Leber

LMI Aerospace to Present at the Oppenheimer & Company Seventh Annual Industrials Conference

ST. LOUIS, May 8, 2012 (GLOBE NEWSWIRE) -- LMI Aerospace, Inc. (Nasdaq:LMIA - News), a leading provider of design engineering services, structural assemblies, kits and components to the aerospace, defense and technology markets, announced today it will present at the Oppenheimer & Company Seventh Annual Industrials Conference to be held at the InterContinental in New York City, May 15 and 16, 2012.

LMI Chief Executive Officer Ronald S. Saks will present for the company on Wednesday, May 16, 2012, from 1:20 p.m. to 1:55 p.m. Eastern Time with accompanying slides. The presentation can be accessed live via the web by using http://www.veracast.com/webcasts/opco/industrials2012/06208296.cfm. A recording of the webcast and presentation slides will be available by accessing the LMI Aerospace Investors Relations page at http://ir.lmiaerospace.com and will remain posted for 90 days.

LMI Aerospace, Inc. is a leading provider of design engineering services and supplier of structural assemblies, kits and components to the aerospace, defense and technology markets. Through its Aerostructures segment, the company primarily fabricates, machines, finishes, integrates, assembles and kits formed close tolerance aluminum and specialty alloy and composite components and higher level assemblies for use by the aerospace, defense and technology industries. It manufactures more than 30,000 products for integration into a variety of aircraft platforms manufactured by leading original equipment manufacturers and Tier 1 aerospace suppliers. Through its Engineering Services segment, operated by its D3 Technologies, Inc. subsidiary, the company provides a complete range of design, engineering and program management services, supporting aircraft product lifecycles from conceptual design, analysis and certification through production support, fleet support and service life extensions via a complete turnkey engineering solution.

The LMI Aerospace, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4971

Visit link:

LMI Aerospace to Present at the Oppenheimer & Company Seventh Annual Industrials Conference

Neuralstem Updates ALS Stem Cell Trial Progress

ROCKVILLE, Md., May 8, 2012 /PRNewswire/ --Neuralstem, Inc. (CUR) announced that the Federal Drug Administration (FDA) has approved the return of three patients from earlier cohorts in its ongoing Phase I safety trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells (HSSC's). These patients will be permitted to return to the trial for second treatments as the next cohort of patients, provided they meet inclusion requirements at the scheduled time. They will be the first to receive stem cell transplantation along the length of the spinal cord.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

The first twelve patients in the trial, which is taking place at Emory University Hospital in Atlanta, Georgia, received stem cell transplants in the lumbar (lower back) region of the spinal cord only. Thelast cohort of three, completed in April, received transplants in the cervical (upper back) region of the spinal cord, where stem cell transplantation could help support breathing, a key function that is lost as ALS progresses. The next cohort of three patients is designed to receive 10 HSSC injections in the lumbar region and 5 in the cervical, for a total of 15 injections along the length of the spinal cord. In the case of the returning patients, who have already received 10 lumbar injections, they will receive five cervical injections. These patients are between 15-17 months out from their first dosing and appear to have tolerated the first procedure well.

Additionally, Neuralstem has submitted a trial amendment to the FDA to increase both the number of patients treated as well as the dose in future cohorts. The amendment would also expand the trial to include certain efficacy endpoints. The trial was initially designed as a safety trial to treat 18 patients.

"The return of these patients to the trial for second treatments is a continuing validation of the trial's safety. Typically, Phase I trials do not bring study subjects back, as that could increase their exposure to potentially harmful treatments," said Karl Johe, PhD, Neuralstem Chairman and Chief Scientific Officer. "Treating these patients who have already received injections in one part of their spine allows us to both increase the overall dosage for each patient as well as transplant them in regions of the spine where they have not been treated," Dr. Johe continued. "Thisnext cohort of patients will be the first in the world to receive stem cell transplants in both cervical and lumbar regions of their spinal cord. With cervical injections of the lumbar patients, for example, we could also potentially support their breathing function, which is vital for preserving quality of life."

"Patients 10-12, who might return to the trial, were among those studied in a paper examining the first safety data from the trial, published online in STEM CELLS last month," said Eva Feldman, MD, PhD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System. "As the paper showed, we believe that the cells and the route of administration are safe. It is a further validation of the safety profile to be able to bring patients back for additional dosing several months past the period which was reported on in the journal." Dr. Feldman is also principal investigator (PI) of the ALS trial and an unpaid Neuralstem consultant.

The FDA-approved amendment to the protocol requires approval of the Emory Institutional Review Board before it can be implemented.

About the Study

The ongoing Phase I study is designed to assess the safety of Neuralstem's spinal cord stem cells (HSSC's) and transplantation technique in up to 18 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

The first twelve patients were all transplanted in the lumbar (lower back) region of the spine. Of these, the initial six (Cohort A) were all non-ambulatory with permanent paralysis. The first patient was treated on January 20, 2010. Successive surgeries have followed at the rate of one every one-to-two months. The first three patients (Cohort A1) were each treated with five unilateral HSSC injections in L2-L4 lumbar segments, while the next three patients (Cohort A2) received ten bilateral injections (5 on each side) in the same region. The next six patients (Cohort B and C) were all ambulatory. Of these, the first three (Cohort B) received five unilateral injections in the L2-L4 region. The last three patients (Cohort C) in this study group received ten bilateral injections in the same region.

Go here to see the original:
Neuralstem Updates ALS Stem Cell Trial Progress

TiGenix : presenting at Key Conferences – Spring 2012

Regulated information May 8, 2012

TiGenix to Present at Key Conferences Spring 2012

Leuven (BELGIUM) - May 8, 2012 - TiGenix (TIG.BR), a leader in the field of cell therapy, announced today that during the months of May and June the company will present at a number of key events in Europe and the U.S. geared at investor, industry, and academic audiences to highlight the commercial potential of ChondroCelect, the only approved cell therapy in Europe, and of the company`s innovative proprietary allogeneic stem cell platform with programs in Phase I, II, and III for a range of inflammatory and autoimmune diseases.

May 15-16 BioEquity, Marriott Hotel, Frankfurt, Germany Presenter: Eduardo Bravo, CEO Date & time: Tuesday, May 15, 16:00-16:25 Room: Level 1, Room Gold 1

May 21-23 World Stem Cells and Regenerative Medicine Congress, Victoria Park Plaza, London, UK Presenter: Eduardo Bravo, CEO Date & time: Monday, May 21, 15:25 -15:50 Title: Cell Therapy & Regenerative Medicine - Progressing into phase III with an orphan indication

May 24 Knowledge for Growth, ICC Ghent, Belgium Presenter: Eduardo Bravo, CEO Time: 11:30 Keynote speech - Advanced therapies: this time it is for real

June 5-8 18th International Stem Cell Therapy Sociey Annual Meeting, Sheraton Seattle, WA, U.S. Presenter: Eduardo Bravo, CEO Date & time: June 7, 13:45-15:15 Title: Plenary Session 4 - Regenerative Medicine and Positioning for Commercial Success - Lessons from the commercial roll out of ChondroCelect in Europe

June 18-21 BIO International Convention, Boston Convention & Exhibition Center, MA, U.S. Presenter: Eduardo Bravo, CEO Date & time: June 20, 15:00-15:45 Title: Stem Cell Therapies...Fact or Fiction?

June 23 VFB Biotech Congres, Leuven, Belgium Location: Imec, Kapeldreef 75, Leuven Presenter: Gil Beyen, Chief Business Officer Time: 11am

June 23 Dag van de Biotechnologie, Leuven, Belgium Location: TiGenix headquarters, Leuven Event: Open day event throughout Flanders for all biotech companies & academic labs Time: 10am-5pm

Read the original:
TiGenix : presenting at Key Conferences - Spring 2012

Researchers Find Unique Physiology Is Key to Diagnosing and Treating Diabetes in Asian Populations

Newswise Boston May 7, 2012 As the diabetes epidemic spreads worldwide, there is growing concern for Asian American populations, who are nearly twice as likely to develop diabetes, particularly type 2 diabetes. Compounding the problem, many of the standard ways to detect diabetes fail in people of Asian descent.

The medical profession needs to be aware of and address the unique characteristics of this population, said George L. King, M.D., Chief Scientific Officer at Joslin Diabetes Center and Professor of Medicine at Harvard Medical School (HMS). Without this understanding, diabetes could be misdiagnosed or missed altogether.

Dr. King was lead author of nine diabetes specialists nationwide who collaboratively wrote an article published in the May 2012 edition of Diabetes Care highlighting a comprehensive range of research findings presented at an international symposium held in Honolulu in September 2011.

The authors compiled extensive data on various groups that comprise the Asian American population, encompassing immigrants from numerous East Asian countries and those born in the United States. They also studied diabetes incidence in Native Hawaiians and Pacific Islanders.

Although there are large differences in immigration patterns and lifestyle adaptations to U.S. culture among these groups, common threads and new insights are emerging. Researchers are finding significant differences in how diabetes affects the bodys chemistry, how to view body weight, and why commonly used laboratory tests may not be reliable in Asian populations.

Type 1 diabetes can be difficult to clinically differentiate from type 2 diabetes in Asians, said Dr. William C. Hsu, M.D., who with Dr. King co-directs the Asian American Diabetes Initiative at Joslin. Dr. Hsu, an Assistant Professor of Medicine at HMS, was lead author of a team of 12 experts who wrote a second article published in the same edition of Diabetes Care. These authors focused on the pathophysiology, or the disease process, of diabetes.

Type 1 diabetes is relatively rare in Asians, with incidence five to 10 times lower than in people of European descent. But diagnosing the disease is more difficult because genetic markers and blood factors generally associated with type 1 diabetes are present in only 30 percent of patients of Asian descent. In other words, simply relying on conventional tests would lead to misdiagnosis of a large percentage of Asians who have type 1 diabetes. More research is needed to learn what other biological factors in Asians patients lead to the destruction of insulin-making beta cells, resulting in type 1 diabetes. Lab tests then could be developed to detect these specific factors.

Type 2 diabetes is the most common form of diabetes in Asian Americans, with prevalence of diagnosed cases in recent years jumping from approximately 1 or 2 percent to 10 percent today, compared with 6 percent in the general population. Many others are undiagnosed or at risk, falling into the "pre-diabetes" category. In type 2 diabetes, the pancreas produces insulin but not enough, or the bodys cells resist its effect. A risk factor commonly associated with type 2 diabetes is excess weight, often measured by calculating the body mass index (BMI).

But for Asian Americans with type 2 diabetes, the average BMI is between 24 and 25, well within the normal BMI range (1925) for the general population.

The BMI in Asian patients can be misleading. They can look quite skinny, Dr. Hsu said. Instead, were learning that a better indicator of type 2 diabetes risk in Asians is fat deposits at the waistline. More research is needed to understand how visceral fat contributes to the onset of type 2 diabetes. If detected in the pre-diabetes stage, the disease often can be prevented.

View original post here:
Researchers Find Unique Physiology Is Key to Diagnosing and Treating Diabetes in Asian Populations

Unique physiology key to diagnosing and treating diabetes in Asian populations

Public release date: 8-May-2012 [ | E-mail | Share ]

Contact: Jeffrey Bright jeffrey.bright@joslin.harvard.edu 617-309-1957 Joslin Diabetes Center

Boston May 7, 2012 As the diabetes epidemic spreads worldwide, there is growing concern for Asian American populations, who are nearly twice as likely to develop diabetes, particularly type 2 diabetes. Compounding the problem, many of the standard ways to detect diabetes fail in people of Asian descent.

"The medical profession needs to be aware of and address the unique characteristics of this population," said George L. King, M.D., Chief Scientific Officer at Joslin Diabetes Center and Professor of Medicine at Harvard Medical School (HMS). "Without this understanding, diabetes could be misdiagnosed or missed altogether."

Dr. King was lead author of nine diabetes specialists nationwide who collaboratively wrote an article published in the May 2012 edition of Diabetes Care highlighting a comprehensive range of research findings presented at an international symposium held in Honolulu in September 2011.

The authors compiled extensive data on various groups that comprise the Asian American population, encompassing immigrants from numerous East Asian countries and those born in the United States. They also studied diabetes incidence in Native Hawaiians and Pacific Islanders.

Although there are large differences in immigration patterns and lifestyle adaptations to U.S. culture among these groups, common threads and new insights are emerging. Researchers are finding significant differences in how diabetes affects the body's chemistry, how to view body weight, and why commonly used laboratory tests may not be reliable in Asian populations.

"Type 1 diabetes can be difficult to clinically differentiate from type 2 diabetes in Asians," said Dr. William C. Hsu, M.D., who with Dr. King co-directs the Asian American Diabetes Initiative at Joslin. Dr. Hsu, an Assistant Professor of Medicine at HMS, was lead author of a team of 12 experts who wrote a second article published in the same edition of Diabetes Care. These authors focused on the pathophysiology, or the disease process, of diabetes.

Type 1 diabetes is relatively rare in Asians, with incidence five to 10 times lower than in people of European descent. But diagnosing the disease is more difficult because genetic markers and blood factors generally associated with type 1 diabetes are present in only 30 percent of patients of Asian descent. In other words, simply relying on conventional tests would lead to misdiagnosis of a large percentage of Asians who have type 1 diabetes. More research is needed to learn what other biological factors in Asians patients lead to the destruction of insulin-making beta cells, resulting in type 1 diabetes. Lab tests then could be developed to detect these specific factors.

Type 2 diabetes is the most common form of diabetes in Asian Americans, with prevalence of diagnosed cases in recent years jumping from approximately 1 or 2 percent to 10 percent today, compared with 6 percent in the general population. Many others are undiagnosed or at risk, falling into the "pre-diabetes" category. In type 2 diabetes, the pancreas produces insulin but not enough, or the body's cells resist its effect. A risk factor commonly associated with type 2 diabetes is excess weight, often measured by calculating the body mass index (BMI).

Originally posted here:
Unique physiology key to diagnosing and treating diabetes in Asian populations

PLUS Diagnostics Opens Houston Laboratory to Serve Southwest Medical Communities

UNION, N.J., May 8, 2012 /PRNewswire/ -- PLUS Diagnostics, a leading anatomic pathology company, opens a new laboratory in Houston, Texas this week, as part of the company's continued national expansion. The new facility offers customized diagnostic testing and consultative services to the gastroenterology and urology specialties, with plans to expand into dermatology and women's health. It will serve physicians and medical specialists across the Southwest region.

The grand opening will be held May 10-11 at the new facility, located at 9150 S. Main Street - Suite C, Houston, TX. Dr. Adnan Savera, chief medical officer for PLUS Diagnostics and a nationally recognized pathologist, will open the new facility, along with the company's employees.

"We are honored to join the Houston business community, and to extend our services to physicians and specialists throughout the Southwest region.We have designed this facility to provide our customers with state-of-the-art, high quality diagnostic services and technologies.We will continue to invest in expanding this lab and our other facilities to offer innovative services that are tailored to meet our customers' unique needs," said David P. Pauluzzi, chief executive officer and president, PLUS Diagnostics.

One of the newest services that PLUS Diagnostics will offer to physicians and surgery centers, is an exclusive molecular diagnostic assay from MDx Health, called Confirm MDx. This new assay is designed to address false-negative biopsy concerns of men undergoing prostate cancer diagnosis and treatment.

PLUS Diagnostics' Houston laboratory is the third facility the company has built in the past three years to support rising demand for its services. In 2009, the company opened a facility in Union, New Jersey and its first West Coast lab in Irvine, California, tripling its overall laboratory capacity. Since partnering with Water Street Healthcare Partners, a strategic private equity firm focused exclusively on the health care industry, PLUS Diagnostics has grown its customer base and increased its net revenues more than 500 percent.

About PLUS Diagnostics

PLUS Diagnostics is a leading national pathology company that provides a full range of multi-specialty services, including extensive diagnostic procedures and specialist consultations. Accredited by the College of American Pathologists, PLUS Diagnostics has long been recognized for exceptional service and quality. The company currently focuses on a broad base of specialty pathology services, including urology, gastroenterology and hematology/oncology. PLUS Diagnostics is a company of Water Street Healthcare Partners. For more information, visit, http://www.plusdx.com.

Go here to read the rest:
PLUS Diagnostics Opens Houston Laboratory to Serve Southwest Medical Communities

Utah’s Schiff Nutrition makes changes to financing for Airborne buy

Schiff Nutrition International Inc., a maker of nutritional supplements, changed the mix on $200 million of loans the company is seeking to support its acquisition of Airborne Inc.

A $150 million term loan was cut to $140 million and will now pay interest at 4.75 percentage points more than the London interbank offered rate, compared with a range of 4.5 percentage points to 4.75 percentage points. Libor, a rate banks say they can borrow in dollars from each other, will have a 1.25 percent floor.

The loan will be due in six years compared with the seven- year maturity originally offered. Schiff is now proposing to sell the debt at 98.5 cents on the dollar, compared with 99 cents earlier proposed. The discount lowers proceeds for the company and boosts the yield to investors.

The Salt Lake City-based company also increased the size of a five-year revolving line of credit to $60 million from $50 million. The revolver pays interest at 4.75 percentage points more than Libor and will be sold to investors at 99 cents.

Royal Bank of Canada and Bank of Montreal are arranging the financing and lenders must submit commitments by 5 p.m. today in New York. The debt is expected to be distributed to investors this week.

Schiff acquired 100 percent of Airbornes stock from GF Capital Private Equity Fund LP for $150 million, according to an April 2 company statement distributed by Business Wire.

Becky Herrick, a spokeswoman for Schiff Nutrition, didnt immediately respond to an e-mail seeking comment.

In a revolving credit facility, money can be borrowed again once its repaid; in a term loan it cant.

Copyright 2012 The Salt Lake Tribune. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Originally posted here:
Utah’s Schiff Nutrition makes changes to financing for Airborne buy

Nutrition’s Heavy Hitters Speak to Magic Valley Dietitians

SUN VALLEY Youd never guess what came out on top of all the energy drinks, energy bars and other products that weekend warriors and professional athletes reach for to refuel after a workout.

Plain old chocolate milk.

Chocolate milk provides both carbohydrates and protein, whereas Gatorade does not, said Nancy Clark, a sports dietitian whose clients include Olympic athletes as well as members of the Boston Red Sox and Boston Celtics.

In one study those who drank chocolate milk after one bout of exercise where able to perform an additional 32 minutes to exhaustion versus 23 minutes for those drinking Gatorade, she said.

I had no idea chocolate milk was so good for you, said Tasha Bradshaw, who teaches Pilates at the new Mind Your Body in Twin Falls.

The virtues of chocolate milk were one of the surprising revelations that Clark listed as she addressed 160 dietitians and others attending the Idaho Academy of Nutrition and Dietetics meeting last week at Sun Valley Resort. The meeting, organized by Magic Valley dietitians, featured some heavy hitters in Clark and Evelyn Tribole, author of Intuitive Eating.

Clark is the word in sports nutrition she walks the walk, said Dr. RoseAnna Holliday, adjunct professor at College of Southern Idaho in Twin Falls. And the eating disorder and weight loss clinics are beginning to base a lot of their work on what Evelyn Tribole has to say.

Shes had 29 years of helping people create healthy relationships with food, said Becky McCarver, a registered dietitian with St. Lukes. Her book completely changed my career.

Tribole said shes having trouble getting on board with the idea that food or sugar can be addictive an idea thats making the rounds at shows like The Dr. Oz Show.

Animals had to be starved to induce the sugar addiction in one of the few studies thats been done on the subject, she said.

Go here to see the original:
Nutrition’s Heavy Hitters Speak to Magic Valley Dietitians

Creative Edge Nutrition, Inc. Strategic Developments

ORLANDO, Fla., May 8, 2012 /PRNewswire/ -- Creative Edge Nutrition, Inc. (Pink Sheets:FITX), is pleased to inform its shareholders that in the last 60 days we have made significant improvements to our corporate structure, business and marketing plans. We are current in our financial information on the OTC markets, completed a name and ticker symbol change.

We are in the process of developing a strategic corporate website to show all of our product lines, distribution channels, manufacturing certifications, strategic business partners and retail vendors which will be linked to Facebook, Twitter, and Linked-In. These business development strategies are being led by the capable leadership of Bill Chaaban, President and Chief Executive Officer, who has developed several multi-million dollar nutritional supplement companies. Additionally, we have been recognized by vendor certification (Vendor Number) from the world's largest nutrition retailer, which has position us for the rolling out and deployment of additional products, sales and retail outlets.

Cenergy will continue to provide timely news updates regarding our strategic business development and marketing plans and will continue our commitment to increase market share, provide shareholder value and measurable results to our partners, distributors, and shareholders. Visit us http://www.CenergyNutrition.com and http://www.facebook.com/pages/Creative-Edge-Nutrition-Inc/115224738609211

About Creative Edge Nutrition, Inc.

Creative Edge Nutrition is a Nutritional Supplement Company focused on developing innovative, high quality supplements. The company offers a broad spectrum of capsules, tablets, and powders, as well as science based products in the principal categories of weight management, nutrition challenges, energy and fitness. The Company manufactures under strict GMP guidelines at GMP Certified and/or FDA registered facilities. http://www.CenergyNutrition.com and http://www.facebook.com/pages/Creative-Edge-Nutrition-Inc/115224738609211

Safe Harbor Notice This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

Contact: Melissa J. Diaz, South Street Media, Inc Phone: (917) 937-8968 Email: Info@southstreetmedia.com

See the original post:
Creative Edge Nutrition, Inc. Strategic Developments

Nutrition a right for children, says former senator

FORMER Senator Deika Morrisan has stressed the importance of nutrition as a fundamental right for children.

Morrison, founder of Do Good Jamaica with its special project Crayons Count, said that a nation can only progress if its children are properly fed.

She was giving the main address at the recent launch of the third annual Nestle Schools Wellness Fiesta, which will be staged over three days from May 10 to 12 at the Jamaica Conference Centre in downtown Kingston.

According to Morrison, the United Nations Children's Fund (UNICEF) made it clear that "inadequate nutrition in life can cause irreparable damage to the developing brain and body, thus the right to nutrition is a fundamental, foundational right for children. She also said that Principle Four of the Convention on the Rights of the Child a human rights treat setting out the civil, political, economic, social, health and cultural rights of children to which Jamaica is a signatory states that "the child shall have the right to adequate nutrition".

Morrison added that Do Good Jamaica's Crayons Count sought not only to provide learning kits to early childhood institutions across Jamaica but to raise awareness of the importance of early childhood education and good early childhood practices. She stressed that nutrition, health and wellness are not just good early childhood practices were all essential practices for all ages.

Noting that Jamaicans do not talk about the critical importance of nutrition enough, she pointed out that the Nestle Schools Wellness Fiesta was therefore a timely opportunity for teachers, caregivers and children to understand how children can get proper nutrition, health and wellness.

The Nestle Schools Wellness Fiesta, targeted at primary and secondary schools with Wellness clubs, will for the first time this year involve secondary school, through the 4-H Clubs, according to Nestle's Consumer Relationship Marketing Manager Angella Black.

On Thursday, the opening day, displays will be presented by the competing primary and secondary schools on the topic 'Active children make healthier adults'. Judging will be on scope of research, accuracy and creativity. Also on the opening day and the remaining two days, there will be the colourful display of the 'Nestle Take a High Five for Life' campaign which will showcase five areas 'Eat Healthy', 'Control Portions', 'Be Active', 'Check Healthy', and 'Be Happy'.

In addition there will be a special focus on physical activity with the wellness fun pavilions that will take the form of an energy zone. There will also be a cooking lab, the Nestle Healthy Kids Programme and the reading pavilion on Saturday, the final day, where representatives of the Jamaica Library Service and Crayons Count will be reading to the children.

A highlight of the launch was the presentation of the Nestle Healthy Kids pledge by Carlah Dume and Renardo Harvey of Lannaman's Preparatory School.

Here is the original post:
Nutrition a right for children, says former senator

MRSAid Photodisinfection Project Wins Innovation Award at Leading Canadian Infectious Disease & Microbiology Conference

Vancouver, B.C. (PRWEB) May 08, 2012

The John Conly Innovation Academy Award was presented to Dr. Titus Wong of Vancouver General Hospital at the AMMI - CACMID Annual Conference held in Vancouver, BC. This inaugural award recognizes novel and creative strategies to improve patient safety and public health in Canada. Dr Wong presented the abstract titled Nasal Decolonization of Staphylococcus aureus with Antimicrobial Photodynamic Therapy (aPDT or photodisinfection) to two of Canada's leading expert groups, the Association of Medical Microbiology and Infectious Disease Canada (AMMI) and the Canadian Association of Clinical Microbiology and Infectious Diseases (CACMID).

Dr. Titus Wong and his team at Vancouver General Hospital (VGH) won the John Conly Innovation Academy Award at the AMMI - CACMID Annual Conference for their implementation of a universal nasal decolonization program using the non-antibiotic photodisinfection based technology, MRSAid(TM), from Vancouver based company Ondine Biomedical Inc. Under this innovative project, patients undergoing major elective surgeries at VGH, including cardiac, spinal, orthopedic, thoracic, vascular, breast reconstruction, and neurological, were treated with MRSAid nasal decolonization therapy prior to surgery. Photodisinfection therapy instantly destroyed the Methicillin resistant staphylococcus aureus (MRSA) and Methicillin sensitive staphylococcus aureus (MSSA) from the patient's nose, the primary site of colonization.

The MRSAid photodisinfection project at VGH is the first deployment of a pre-surgical universal nasal decolonization protocol. To date, results have demonstrated patient safety, microbiological efficacy and high patient compliance rates of 99%. Traditional decolonization protocols involve the use of topical antibiotics which have demonstrated resistance formation(1) and patient compliance rates as low as 40%(2) Additionally, ease of workflow integration of the MRSAid photodisinfection system was demonstrated on this patient population of over 1,800. Photodisinfection rapidly destroys pathogens and associated virulence factors without the need for antibiotics, and without encouraging the formation and spread of antibiotic resistance.

Patients colonized with MRSA and MSSA are at risk of developing surgical site infections, which often lead to increased morbidity and mortality rates. Patients that develop infections after surgery are five times more likely to be readmitted to a hospital and twice as likely to die. On average, surgical site infections require an extended hospital stay of eight days in an acute care setting, and add hundreds of millions of dollars in additional costs to the Canadian healthcare system every year. The objective of this patient safety initiative is to significantly reduce surgical site infection rates.

Dr. Titus Wong and his team at VGH expect to complete this quality improvement project by the end of the year and will publish safety, microbiological efficacy, patient compliance and surgical site infection rates throughout 2013.

(1) Coates T, Bax R, Coates A (2009). Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. J Antimicrob Chemother. Jul;64(1):9-15. (2) Claxton, A. J., Cramer, J. & Pierce, C. (2001). A systematic review of the association between dose regimens and medication compliance. Clinical Therapeutics23, 1296310.

About Ondine Biomedical Inc. Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratories in Bothell, Washington, USA and Minneapolis, Minnesota. Please visit the Company's website at: http://www.ondinebio.com and http://www.ondineblog.com. For further information please contact us at: Ondine Biomedical Inc. info(at)ondinebio(dot)com

Read the original post:
MRSAid Photodisinfection Project Wins Innovation Award at Leading Canadian Infectious Disease & Microbiology Conference